Presentation Number: LBA53. Lecture Time: 09:15-09:30. Speakers: Federico Cappuzzo (Ravenna, IT) Background

Transcription

1 LBA3 - IMpower30: Progressio-free survival (PFS) ad safety aalysis from a radomised phase 3 study of carboplati + ab-paclitaxel (CP) with or without atezolizumab (atezo) as first-lie (L) therapy i advaced o-squamous NSCLC Presetatio Number: LBA3 Lecture Time: 0: - 0:30 Speakers: Federico Cappuzzo (Ravea, IT) Backgroud Atezo (ati-pd-l) mootherapy improves overall survival (OS) vs docetaxel i 2L+ NSCLC, regardless of PD-L status; phase 3, L studies have show the cliical beefit of atezo plus chemotherapy. IMpower30 (NCT023778) evaluated atezo + CP vs CP i patiets (pts) with measurable (RECIST v.) stage IV o-squamous NSCLC. Methods Pts (radomised 2:) received atezo (200 mg IV q3w) + CP (carboplati: AUC q3w; ab-paclitaxel: 00 mg/m 2 IV qw) (Arm A) or CP (Arm B), for 4 or 2-day cycles ad maiteace (Arm A: atezo util loss of cliical beefit; Arm B: best supportive care or pemetrexed q3w util disease progressio [PD]). Crossover to atezo at PD was iitially permitted for Arm B pts. Co-primary edpoits: ivestigator-assessed PFS ad OS (ITT-WT populatio: EGFR-WT/ALK-egative). Secodary edpoits: OS ad PFS (ITT populatio ad by PD-L expressio), respose rate ad safety. ITT populatio could be formally tested for OS/PFS if ITT-WT OS was positive. Results 723 ITT (7 ITT-WT) pts were erolled. Statistically sigificat, cliically meaigful improvemets i OS ad statistically sigificat improvemets i PFS (ITT ad ITT-WT) were observed i Arm A vs Arm B (table). PFS ad OS beefit was observed i all PD-L subgroups, ad cosistetly across all subgroups, except i pts with liver metastases ad EGFR/ALK geomic alteratios. I treated pts, 73.2% (Arm A) vs 0.3% (Arm B) had grade 3 4 treatmet-related adverse evets.

2 Table. IMpower30 Efficacy Aalyses Arm A Atezo + CP Arm B CP ITT-WT =4 =8 Media OS (% CI) 8. mo (.0 2.2) 3. mo ( ) HR (% CI; P value) 0.7 ( ; 0.033) 2-mo OS (% CI) 3.% (8. 7.).% ( ) Media PFS (% CI) 7.0 mo (.2 7.3). mo (4.4.) HR (% CI; P value) 0.4 ( ; <0.000) 2-mo PFS (% CI) 2.% ( ) 4.% ( ) =447 = Cofirmed ORR (ivestigator assessed) (% 4.2% ( ) 3.% ( ) CI) =0 =72 Media DOR (% CI) 8.4 mo (..8). mo (. 7.) PD-L high a =88 =42 Media OS (% CI) 7.4 mo (4.78 NA). mo (0.4 NA) HR (% CI) 0.84 (0..3) Media PFS (% CI).4 mo (.4.7) 4. mo (3. 7) HR (% CI) 0. ( ) PD-L low a =28 = Media OS (% CI) 23.7 mo (8.3 NA). mo (2.32.3) HR (% CI) 0.70 (0.4.08) Media PFS (% CI) 8.3 mo (7. 0.3).0 mo (.2.3) HR (% CI) 0. ( ) PD-L egative a =23 =2 Media OS (% CI).2 mo (2.88.) 2.0 mo ( ) HR (% CI) 0.8 (0..08) Media PFS (% CI).2 mo (.2 7.) 4.7 mo (4..72) HR (% CI) 0.72 (0. 0.) ITT =483 =240 Media OS (% CI) 8. mo ( ) 3. mo ( ) HR (% CI; P value) 0.80 (0. 0.; 0.03) Media PFS (% CI) 7.0 mo (.3 7.3). mo (4..) HR (% CI; P value) 0. ( ; <0.000) a PD-L high (TC3 or IC3): Patiets with PD-L expressio i 0% of tumour cells or 0% of tumour-ifiltratig immue cells; PD-L low (TC/2 or IC/2): Patiets with PD-L expressio i % ad <0% of tumour cells or % ad <0% of tumour-ifiltratig immue cells; ad PD-L egative (TC0 ad IC0): Patiets with PD-L expressio i <% of tumour cells ad <% of tumour-ifiltratig immue cells. Data cut-off: March 208. Miimum follow up: 3 moths. NCT

3 DOR, duratio of respose; HR, hazard ratio; IC, immue cells; ORR, objective respose rate; OS, overall survival; PFS, progressio-free survival; TC, tumour cells. Coclusios Overall, IMpower30 showed statistically sigificat, cliically meaigful improvemets i OS ad statistically sigificat improvemets i PFS with atezo + CP, vs CP, i L, stage IV o-squamous NSCLC, i this predomiatly ITT-WT populatio. No ew safety sigals were idetified. Cliical trial idetificatio: NCT (20 February 20). Editorial Ackowledgemet Support for third-party writig assistace for this abstract, furished by Islay Steele, PhD, of Health Iteractios, was provided by F. Hoffma-La Roche Ltd, Basel, Switzerlad.

4 LBA4 - IMpower32: efficacy of atezolizumab (atezo) + carboplati (carbo)/cisplati (cis) + pemetrexed (pem) as L treatmet i key subgroups with stage IV o-squamous osmall cell lug cacer (NSCLC) Presetatio Number: LBA4 Lecture Time: 0:30-0:4 Speakers: Fabrice Barlesi (Marseille, FR) Backgroud The global Phase III IMpower32 study evaluated the additio of atezo to platium-based pem combiatios as L treatmet (tx) for patiets (pts) with metastatic o-squamous NSCLC tumours lackig sesitizig EGFR or ALK mutatios. IMpower32 met its co-primary edpoit of PFS i the ITT populatio ad showed umerical improvemets i OS. We performed exploratory efficacy aalyses to assess cliical beefit i key subgroups. Methods Previously utreated pts were radomized : to receive 4 or cycles of either atezo 200 mg + carbo AUC or cis 7 mg/m 2 + pem 00 mg/m 2 (Arm APP) or carbo AUC or cis 7 mg/m 2 + pem 00 mg/m 2 (Arm PP), followed by maiteace therapy with atezo 200 mg + pem 00 mg/m 2 (APP) or pem 00 mg/m 2 aloe (PP). Atezo maiteace tx could be cotiued beyod disease progressio. We coducted exploratory efficacy aalyses examiig PFS ad iterim OS i cliically relevat pt subgroups (race, age, smokig history, ad liver metastasis at baselie). Results 78 pts were erolled. The media follow-up at data cutoff (May, 208) was 4.8 mo. Baselie characteristics were mostly balaced betwee tx arms. See table for PFS ad iterim OS data i key subgroups. Additioal efficacy ad safety data will be preseted. Coclusios The additio of atezo to carbo or cis + pem resulted i umerical improvemet i PFS ad OS i most key cliical subgroups. Survival beefit appeared more proouced i Asia pts, older pts, ad ever smokers. Further aalyses may provide ew isights ito the mechaisms uderlyig these effects ad may improve future tx optios for pts globally.

5 Table Populatio APP PP ITT 2 2 Media PFS (% 7. (., 8.) 28 Media PFS (%.2 (4.3,.) 0. (0.44, 0.7); P < a HR (% CI); P value No-Asia (0.3, 0.8) Asia (0.028, 0.3) < y (0.4, 0.80) y (0.42, 0.73) Never smokers Former/curre t smokers (0.28, 0.87) (0.0, 0.74) No liver mets (0.4, 0.) Liver mets (0.47,.) Media OS (% Media OS HR (% CI); (% P value ITT (3.0, NE) (.4,.) 0.83 (0.44,.0) P = a No-Asia (0.4,.0) Asia 7 NE NE 0.8 (0.37,.24) < y (0.2,.2) y (0.0,.0)

6 Never smokers Former/curre t smokers (0.32,.30) (0.,.0) No liver mets (0., 0.8) Liver mets (0.7,.70) a Stratified. Cliical trial idetificatio: NCT07434 Editorial Ackowledgemet: Steffe Biechele, PhD, of Health Iteractios